DOUGLAS S. ROSS, M.D.; E. CHESTER RIDGWAY, M.D.; GILBERT H. DANIELS, M.D.
Forty-five patients with solitary toxic thyroid adenomas received 131I (mean dose, 10.3 mCi) for treatment of hyperthyroidism and were followed for 4.9 ± 3.2 years (range, 0.5 to 13.5). Seventy-seven percent were euthyroid by 2 months, 91% by 6 months, and 93% by 1 year. Only 3 patients did not respond to a single dose of 131I, but all responded to multiple doses. Late recurrent hyperthyroidism occurred in 3 patients at 4.5, 6, and 10 years after treatment with a single dose of 131I. No patient developed clinical hypothyroidism, and none had a low serum thyroxine level associated with an elevated serum thyrotrophin level. Three patients developed minimal elevations in serum thyrotrophin levels: 1, 4, and 7. 5 years after 131I treatment, their thyrotrophin levels were 8.4, 6.2, and 9.6 µU/mL, respectively. All 3 had normal serum thyroxine levels and were clinically euthyroid. Mean serum thyroxine concentrations of all patients were unchanged between 1 and more than 9 years of follow-up. These data suggest that solitary toxic adenomas may be treated with relatively low doses of 131I (5 to 15 mCi), and that post-treatment hypothyroidism is very unusual.
ROSS DS, RIDGWAY EC, DANIELS GH. Successful Treatment of Solitary Toxic Thyroid Nodules with Relatively Low-Dose Iodine-131, with Low Prevalence of Hypothyroidism. Ann Intern Med. 1984;101:488–490. doi: 10.7326/0003-4819-101-4-488
Download citation file:
Published: Ann Intern Med. 1984;101(4):488-490.
Endocrine and Metabolism, Endocrine Cancer, Hematology/Oncology, Thyroid Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use